Kymera Therapeutics (KYMR) to Release Quarterly Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Kymera Therapeutics to post earnings of ($0.78) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $85.11 on Thursday. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00. The company has a market cap of $6.12 billion, a P/E ratio of -23.71 and a beta of 2.21. The stock’s fifty day moving average price is $77.77 and its 200-day moving average price is $63.04.

Insiders Place Their Bets

In other news, Director Bruce Booth sold 229,809 shares of Kymera Therapeutics stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total transaction of $21,080,379.57. Following the transaction, the director owned 686,477 shares in the company, valued at $62,970,535.21. This trade represents a 25.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $89.76, for a total value of $448,800.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 420,895 shares of company stock valued at $37,778,351. 16.01% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its stake in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC lifted its holdings in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. boosted its position in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Kymera Therapeutics in the fourth quarter worth $63,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at $73,000.

Analysts Set New Price Targets

KYMR has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Mizuho boosted their price objective on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. UBS Group upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a report on Thursday, December 4th. HC Wainwright lifted their target price on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Truist Financial increased their price target on Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Buy” and a consensus target price of $117.00.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.